| ¿µ¹® | solid tumor | ÇÑ±Û | °íÇüÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷·Î ²Ë Âù Á¾¾çÀ» ¸»ÇÔ. ¹éÇ÷º´ µîÀÇ Ç÷¾×¾Ï°ú °°ÀÌ ÇüŸ¦ ÃëÇÏÁö ¾Ê°í ¾×üÀÎ »óÅÂÀÇ ¾Ï°ú ´ëÁ¶µÇ´Â ¿ë¾î·Î¼ ´Ü´ÜÇÑ µ¢¾î¸®·Î ±¸¼ºµÈ ¾Ç¼ºÁ¾¾çÀÌ´Ù. ´ëºÎºÐÀÇ Á¾¾çÀÌ ÀÌ¿¡ ÇØ´çÇÑ´Ù. ƯÈ÷ Ç¥ÇÇÁ¶Á÷¿¡¼ ±â¿øÇÑ Á¾¾çÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | ulcerating tumor | ÇÑ±Û | ±Ë¾ç¼º Á¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¾¾çÀÇ Ç¥¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇÏ´Â °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇÏ´Â °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ. |
||
| ¿µ¹® | brain tumor | ÇÑ±Û | ³úÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼ »ý±ä Á¾¾çÀ» ÁöĪÇÏ´Â ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀÎ µÎ°³°¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù. ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀÎ µÎ°³°¿¡¼ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀÎ Á¶Á÷À» ¾Ð¹ÚÇÏ°Ô µÇ°í, µÎ°³°³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Ư¡¿¡ ÀÇÇØ¼ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀÎ ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀÎ ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇÏ´Â ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù. |
||
| ¿µ¹® | epithelial tumor | ÇÑ±Û | »óÇǼºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¤»ó »ç¶÷ÀÇ Á¶Á÷Àº üǥ¸éÀ» µ¤´Â ¿ªÇÒÀ» ÇÏ´Â Á¶Á÷°ú, ÁÖ·Î ¹ß»ý±âÀÇ Á߹迱¿¡¼ ºÐÈÇÑ °£¿±Á¶Á÷¿¡¼ À¯·¡ÇÏ´Â °áÇÕÁ¶Á÷, »À, ¿¬°ñ, Áö¹æ, ±ÙÀ°, Ç÷°ü µîÀÇ Á¶Á÷ÀÇ µÎ °èÅëÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ÀüÀÚ¸¦ »óÇǼº Á¶Á÷, ÈÄÀÚ¸¦ ºñ»óÇǼº Á¶Á÷À̶ó ÇÏ¸ç ±× °¢°¢À» ±¸¼ºÇÏ´Â ¼¼Æ÷¸¦ »óÇǼº ¼¼Æ÷, ºñ»óÇǼ¼Æ÷¶ó ÃÑĪÇÑ´Ù. »óÇǼº ¼¼Æ÷¿¡¼ ±â¿øÇÏ´Â Á¾¾çÀÌ »óÇǼº Á¾¾çÀ̸ç, ±ÙóÀÇ Á¶Á÷À¸·Î ħÅõ³ª Ç÷·ù, ¸²ÇÁÀÇ Á¶Á÷À» Ÿ°í ¿ø°Å¸®ÀÇ Àå±â·Î À̵¿ÇÏÁö ¾Ê´Â ¾ç¼ºÁ¾¾ç¿¡´Â ¼±Á¾, À¯µÎÁ¾ µîÀÌ ÀÖ°í ¾ç¼º°ú ¹Ý´ë·Î ±ÙóÀÇ Á¶Á÷À¸·Î ħÅõ, ¿ø°ÝÀå±â·Î ÀüÀÌÇÏ´Â ¾Ç¼ºÁ¾¾çÀ» ¸ðµÎ ÅëĪÇÏ¿© ¾ÏÁ¾(carcinoma)À̶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | medullary tumor | ÇÑ±Û | ¼öÁú¼º Á¾¾ç |
|---|---|---|---|
| ¼³¸í | ¾ÏÀÇ º´¸®ÇÐÀûÀÎ ºÐ·ùÁß Çϳª. ¿©·¯ ±â°üÀÇ ¾Ï¿¡¼ ³ªÅ¸³ª´Âµ¥ ÁÖ·Î °©»ó»ù¾ÏÀ̳ª À¯¹æ¾Ï¿¡¼ º¸ÀδÙ. |
||
| TIL | tumor-infiltrating leukocyte; tumor-infiltrating lymphocyte |
|---|---|
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| BT | base of tongue; bedtime; bitemporal; bitrochanteric; bladder tumor; Blalock-Taussig [shunt]; bleedin... |
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
| TNM | primary tumor, regional nodes, metastasis [tumor staging]; thyroid node metastases; tumor node metas... |
| TIL | Tumor Infiltrating Lymphocytes |
|---|---|
| TIL | tumor infiltrating leukocytes |
| GIC | Graft-infiltrating cells |
| GIL | Graft-infiltrating lymphocytes |
| IDC | Infiltrating ductal carcinoma |
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
|---|---|
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| carcinoma, infiltrating duct | An invasive (infiltrating) carcinoma of the breast. This carcinoma in which no special histological feature is recognised is designated nos or not otherwise specified and is by far the most common ductal tumour, accounting for almost 70% of breast cancers. It is characterised by stony hardness upon palpation. It commonly metastasizes to the axillary lymph nodes and its prognosis is the poorest of the various ductal types. (12 Dec 1998) |
| infiltrating | <pathology> Refers to a tumour that penetrates the normal, surrounding tissue. (13 Nov 1997) |
| infiltrating cancer | <oncology> Cancer that has grown through the cell wall of the breast area, in which it originated, and into surrounding tissues. (13 Nov 1997) |
| infiltrating ductal cell carcinoma | <oncology, tumour> A cancer that begins in the mammary glands and has spread to areas outside the gland. (13 Nov 1997) |
| infiltrating lipoma | A malignant tumour derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (liposarcoma, myxoid), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (12 Dec 1998) |
| tumour-infiltrating lymphocyte | <haematology, oncology> Special cancer-fighting cells of the immune system found in tumours. In a type of experimental therapy, scientists harvest these cells from the tumour, grow them in a laboratory and then return them to the patient with the hope of the cells destroying the tumour. These cells can be collected from the site of a tumour and exposed to IL-2 in vitro. When these cells are injected back into the tumour bearing host, they will specifically kill the tumour from which they originated. (05 Mar 2000) |
| lymphocytes, tumour-infiltrating | Lymphocytes that show specificity for autologous tumour cells. Ex vivo isolation and culturing of til with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|